Connor, Clark & Lunn Investment Management (CC&L)
SGMO

Connor, Clark & Lunn Investment Management (CC&L)’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-349,894
Closed -$1.1M – 1432
2022
Q4 		$1.1M Sell
349,894
-255,044
-42% -$990K 0.01% 679
2022
Q3 		$2.96M Buy
604,938
+218,812
+57% +$1.12M 0.02% 419
2022
Q2 		$1.6M Buy
386,126
+271,712
+237% +$1.17M 0.01% 515
2022
Q1 		$665K Sell
114,414
-24,745
-18% -$147K ﹤0.01% 729
2021
Q4 		$1.04M Sell
139,159
-150,869
-52% -$1.31M 0.01% 672
2021
Q3 		$2.61M Buy
290,028
+105,116
+57% +$1.04M 0.01% 468
2021
Q2 		$2.21M Buy
184,912
+94,506
+105% +$1.07M 0.01% 518
2021
Q1 		$1.13M Sell
90,406
-46,857
-34% -$631K 0.01% 672
2020
Q4 		$2.14M Buy
137,263
+119,470
+671% +$1.4M 0.01% 498
2020
Q3 		$168K Buy
+17,793
New +$192K ﹤0.01% 852
2017
Q2 		– Sell
-55,509
Closed -$289K – 930
2017
Q1 		$289K Sell
55,509
-1,700
-3% -$6.82K ﹤0.01% 733
2016
Q4 		$174K Sell
57,209
-12,900
-18% -$47K ﹤0.01% 805
2016
Q3 		$325K Sell
70,109
-93,600
-57% -$476K ﹤0.01% 658
2016
Q2 		$948K Sell
163,709
-123,100
-43% -$785K 0.01% 477
2016
Q1 		$1.74M Sell
286,809
-70,700
-20% -$425K 0.01% 355
2015
Q4 		$3.26M Buy
357,509
+74,625
+26% +$575K 0.03% 268
2015
Q3 		$1.59M Buy
282,884
+179,312
+173% +$1.48M 0.01% 330
2015
Q2 		$1.15M Sell
103,572
-23,100
-18% -$298K 0.01% 314
2015
Q1 		$1.99M Sell
126,672
-10,500
-8% -$162K 0.02% 234
2014
Q4 		$2.09M Buy
137,172
+88,672
+183% +$1.08M 0.02% 219
2014
Q3 		$523K Buy
+48,500
New +$633K ﹤0.01% 382
2014
Q2 		– Sell
-53,400
Closed -$1.07M – 620
2014
Q1 		$1.07M Buy
53,400
+35,600
+200% +$686K 0.01% 371
2013
Q4 		$263K Sell
17,800
-25,100
-59% -$289K ﹤0.01% 624
2013
Q3 		$463K Buy
42,900
+18,700
+77% +$186K ﹤0.01% 376
2013
Q2 		$199K Buy
+24,200
New +$211K ﹤0.01% 474

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SGMO Position: Q1 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2023, closing a stake of 349,894 shares — an estimated $1.1M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SGMO in Q2 2013 and held it in 25 quarters. The position peaked at $3.26M in Q4 2015. 179 funds tracked by Wall St. Rank hold SGMO as of Q1 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 349,894 SANGAMO THERAPEUTICS INC shares in Q1 2023, an estimated $1.1M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 25 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s SANGAMO THERAPEUTICS INC position peaked at $3.26M in Q4 2015.
  • 179 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2023, filed 10 May 2023.